Skip to main content
. 2016 Dec 21;23(6):e589–e597. doi: 10.3747/co.23.3273

FIGURE 5.

FIGURE 5

Overall survival stratified by treatment received after discontinuation of crizotinib. Patients were censored if no further data were collected (that is, the date of last data collection occurred before death). Median overall survival was 0.9 months in patients who received no treatment after crizotinib, 7.6 months in those who received no ceritinib treatment after crizotinib, and 20.4 months in those who received ceritinib treatment after crizotinib (p < 0.0001).